Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

<< Previous

Bullboard Posts

Next >>

Post by Wanwanesportson Dec 02, 2020 3:43pm

299 Views

Post# 32019918

The Future

These other companies financials also indicate a company poised to grow along with DeFi. While it is always important to do extra due diligence on micro-cap investment companies. Would you mind to see this before it's too late?

Added to that, These companies ROA approximately 109.9% and Gross Profit Margin 100%, indicate a healthy company that is able to generate an efficient profit from its total assets and total revenue.

These are the companies positioning itself in a growth industry trading at a grossly undervalued price with some actual strong technicals to back it up. Check disclaimer on my profile.

<< Previous

Bullboard Posts

Next >>

Thesis Gold makes high-grade discovery at Ring Zone